Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625997 | 1.00 | PTGDR2 (0.52) | PTGDR2CCR1GPR119MGLLSETD7 | |
| SCHEMBL3664004 | 0.89 | MGLL (0.49) | PTGDR2CCR1GPR119MGLL | |
| SCHEMBL3664002 | 0.89 | MGLL (0.49) | PTGDR2CCR1GPR119MGLL | |
| SCHEMBL7968974 | 0.89 | MGLL (0.49) | PTGDR2CCR1GPR119MGLL | |
| SCHEMBL1704761 | 0.89 | CCR1 (0.44) | PTGDR2CCR1GPR119MGLLSETD7 | |
| SCHEMBL29269208 | 0.88 | CCR1 (0.47) | PTGDR2CCR1GPR119MGLLSETD7 | |
| SCHEMBL29269210 | 0.88 | CCR1 (0.47) | PTGDR2CCR1GPR119MGLLSETD7 | |
| SCHEMBL29269207 | 0.88 | CCR1 (0.47) | PTGDR2CCR1GPR119MGLLSETD7 | |
| SCHEMBL1704225 | 0.88 | PTGDR2 (0.55) | PTGDR2CCR1GPR119OPRK1 | |
| SCHEMBL377466 | 0.87 | CCR1 (0.46) | PTGDR2CCR1GPR119MGLLSETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2441763-A1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | Glaxo Group Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | PTGDR2 37/4885CCR1 1073/4885GPR119 12/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | PTGDR2 115/4885CCR1 900/4885GPR119 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.